Boston Trust Walden Corp Buys 146 Shares of Danaher Corporation $DHR

Boston Trust Walden Corp grew its stake in shares of Danaher Corporation (NYSE:DHR) by 0.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,438 shares of the conglomerate’s stock after buying an additional 146 shares during the period. Boston Trust Walden Corp’s holdings in Danaher were worth $8,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Nuveen LLC bought a new position in shares of Danaher during the 1st quarter valued at approximately $833,941,000. Invesco Ltd. boosted its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after acquiring an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after acquiring an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after acquiring an additional 722,636 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Finally, Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $244.60.

Danaher Stock Performance

DHR stock opened at $206.19 on Wednesday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business’s fifty day simple moving average is $200.96 and its two-hundred day simple moving average is $197.13. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The firm has a market cap of $147.64 billion, a price-to-earnings ratio of 43.87, a PEG ratio of 2.92 and a beta of 0.77.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the firm posted $1.72 earnings per share. The business’s revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insiders Place Their Bets

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 11.20% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.